Abstract

Pulmonary arterial hypertension is an uncommon but disabling and often fatal condition, in which there is a sustained rise in pulmonary arterial pressure due to progressive obliteration of the pulmonary vascular bed. ▼Bosentan (Tracleer - Actelion), which belongs to a new class of drugs called endothelin receptor antagonists, is now available for treating patients with pulmonary arterial hypertension.1 Here we assess whether bosentan offers worthwhile benefits in the management of patients with this condition.